Skip to main content

Steatohepatitis, Nonalcoholic (NASH)

Anuja Abhyankar, MD Reviewed 06/2022
 


BASICS

DESCRIPTION

  • Nonalcoholic steatohepatitis (NASH) is a chronic liver disease causing hepatocellular injury and inflammation due to the accumulation of fat.

  • NASH is an inflammatory sub...

DIAGNOSIS

HISTORY

  • Most patients with NAFLD and NASH are asymptomatic.

  • In symptomatic patients, malaise, fatigue, nausea, and right upper quadrant discomfort are most common.

  • Review history for comorbid c...

TREATMENT

Maximize control of comorbidities, and avoid factors that promote progression of liver disease. 

GENERAL MEASURES

  • Weight loss of at least 5-7% of body weight helps stabilize steatosis. Greater...

ONGOING CARE

FOLLOW-UP RECOMMENDATIONS

  • All patients should be tested for hepatitis A and B and vaccinated, if not immune.

  • Consider screening patients with NASH cirrhosis for hepatocellular carcinoma acc...

REFERENCES

1
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review JAMA. 2020;323(12):1175–1183. Published correction appears in JAMA. 2020;323(16):1619.
2
C...

ADDITIONAL READING

  • Leoni S, Tovoli F, Napoli L, et al. Current guidelines for the management of non- alcoholic fatty liver disease: a systematic review with comparative analysis. ...

CODES

ICD10

  • K75.81 Nonalcoholic steatohepatitis (NASH)

  • K76.0 Fatty (change of) liver, not elsewhere classified

SNOMED

  • 442685003 nonalcoholic steatohepatitis (disorder)

  • 197315008 Non-alcoholic fatty liver (...

CLINICAL PEARLS

  • The prevalence of NAFLD and NASH is higher in patients with metabolic syndrome or any one of its components (diabetes, obesity, hypertriglyceridemia).

  • Liver biopsy is the gold standard ...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

×